Towa Pharmaceutical concluded a basic agreement for a collaboration framework in pharmaceutical manufacturing with Otsuka Pharmaceutical on January 21, 2026, aiming for stable supply of off-patent drugs.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4553","jir_company_name":"Towa Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-01-21","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/01\/4553-20260121-01.pdf","jir_short_summary":"Towa Pharmaceutical concluded a basic agreement for a collaboration framework in pharmaceutical manufacturing with Otsuka Pharmaceutical on January 21, 2026, aiming for stable supply of off-patent drugs.","jir_summary":"### Overview of Collaboration\nTowa Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. signed a basic agreement on January 21, 2026, to establish a strategic collaboration framework for pharmaceutical manufacturing. Through succession and contract manufacturing of certain pharmaceuticals held by Otsuka Pharmaceutical, and licensing utilization of strategically collaborative products, they aim to ensure stable supply of pharmaceuticals. The initiative focuses on succession and contract manufacturing to secure stable supply of long-listed products and establishing a mutual backup system, with sequential commencement planned as production preparations are completed from the fiscal year ending March 2026 onwards.\n\n### Background and Future Outlook\nIn response to the government\u2019s industrial structure reform recommendations, supply instability in the generic pharmaceutical industry has become a social issue. Both companies promote comprehensive collaboration beyond the boundaries of original drug and generic drug companies. They aim to contribute to sustainable growth in the off-patent drug market and improve the sustainability of the domestic pharmaceutical industry. The impact on fiscal year ending March 2026 performance is expected to be minor, while contributing to performance improvement over the medium to long term.","jir_financial_highlights":"Impact on FY ending March 2026 Performance: Minor (Unknown)","jir_category":"","jir_hashtags":"#TowaPharmaceutical, #M&A, #PharmaceuticalCollaboration","jir_key_figures":"Basic Agreement Conclusion Date: 2026-01-21\nImpact on FY ending March 2026 Performance: Minor\n14% of all prescription pharmaceuticals (2,208 items) face shipment restrictions or supply suspension (as of October 2025)","jir_meta_title":"Towa Pharmaceutical Aims for Stable Supply through Basic Agreement on Pharmaceutical Manufacturing Collaboration with Otsuka Pharmaceutical","jir_meta_description":"On January 21, 2026, Towa Pharmaceutical signed a basic agreement with Otsuka Pharmaceutical to establish a collaboration framework in pharmaceutical manufacturing, aiming for stable supply of off-patent drugs with sequential production starting from fiscal year ending March 2026.","jir_og_title":"Towa Pharmaceutical Concludes Basic Agreement on Pharmaceutical Manufacturing Collaboration with Otsuka Pharmaceutical","jir_og_description":"Towa Pharmaceutical has concluded a basic agreement with Otsuka Pharmaceutical to establish a collaboration framework for pharmaceutical manufacturing, aiming for stable supply of off-patent drugs.","jir_og_image_url":"\/assets\/og\/company-m_and_a_alliance.jpg","jir_chart_data_collection":"[]","ir_related_company":9026,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-20052","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n